Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1and programmed death-ligand 1 inhibitors: A protocol for systematic review and meta-analysis

Ítems similars

• Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer protocol for a systematic review and network meta-analysis: A protocol for systematic review
  per: Han, Deting, et al.
  Publicat: (2020)
• Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer
  per: Zhao, Bin, et al.
  Publicat: (2020)
• Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers
  per: Maughan, Benjamin L., et al.
  Publicat: (2017)
• Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis
  per: Wang, Xuewen, et al.
  Publicat: (2020)
• The incidence of pseudoprogressive disease associated with programmed cell death 1/programmed cell death ligand 1 inhibitors: A meta-analysis
  per: Zhang, Jingyi, et al.
  Publicat: (2021)